Response of severe systemic mastocytosis to interferon alpha

British Journal of Dermatology

Volumn 138, Issue 3, 1998, Pages 489-495

  Butterfield, J H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLIMIDAZOLEACETIC ACID; RECOMBINANT ALPHA2B INTERFERON; TRYPTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; BONE MARROW CELL; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHYROIDISM; MALE; MASTOCYTOSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; URINARY EXCRETION;

AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; MASTOCYTOSIS; MIDDLE AGED; PRURITUS; URTICARIA PIGMENTOSA;

EID: 0031943841     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02131.x     Document Type: Article

References (34)

1. Webb TA, Li C-Y, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer 1982; 49: 927-38.
2. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology 1979; 3: 349-65.
3. Cryer PE, Kissane JM (eds). Systemic mastocytosis (Clinicopathologic Conference). Am J Med 1976; 61: 671-80.
4. Travis WD, Li C-Y, Bergstralh EJ et al. Systemic mast cell disease: analysis of 58 cases and literature review. Medicine (Baltimore) 1988; 67: 345-68.
5. Tharp MD. The spectrum of mastocytosis. Am J Med Sci 1985; 289: 119-32.
6. Lo WL, Wong CK. Systemic mastocytosis - case report and literature review. J Dermatol 1987; 14: 483-90.
7. Hirschowitz BI, Groarke JF. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytoses. Ann Intern Med 1979; 90: 769-71.
8. Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979; 301: 465-9.
9. Yocum MW, Butterfield JH, Gharib H. Increased plasma calcitonin levels in systemic mast cell disease. Mayo Clin Proc 1994; 69: 987-90.
10. Butterfield JH, Kao PC, Klee GC, Yocum MW, Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc 1995; 70: 481-7.
11. Roberts LJ II, Turk JW, Oates JA. Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks. Adv Shock Res 1982: 8: 145-52.
12. Turk J, Oates JA, Roberts LJ II. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 1983; 71: 189-92.
13. Roberts LJ II, Sweetman BJ. Lewis RA et al. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980; 303: 1400-4.
14. Mutter RD, Tannenbaum M, Ultmann JE. Systemic mast cell disease. Ann Intern Med 1963; 59: 887-906.
15. Fishman RS, Fleming CR, Li C-Y. Systemic mastocytosis with review of gastrointestinal manifestations. Mayo Clin Proc 1979; 54: 51-4.
16. Gonnella JS, Lipsey AI. Mastocytosis manifested by hepatosplenomegaly: report of a case. N Engl J Med 1964; 271: 533-5.
17. Kluin-Nelemans HC, Jansen JH, Breukelman H et al. Response to Interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992; 326: 619-23.
18. Sun T, Li C-Y, Yam LT. Atlas of Cytochemistry and Immunochemistry of Hematologic Neoplasms. Chicago: American Society of Clinical Pathologists Press, 1985; 121.
19. Sostre S, Handler HL. Bony lesions in systemic mastocytosis: scintigraphic evaluation. Arch Dermatol 1977; 113: 1245-7.
20. Schwartz LB, Metcalfe DD, Miller JS et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-6.
21. Keyzer JJ, de Monchy JG, van Doormaal JJ, van Voorst Vader PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983; 309: 1603-5.
22. Talpaz M, Kantarjian H, Kurzrock R et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532-8.
23. Ratain MJ, Golomb HM, Bardawil RG et al. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood 1987; 69: 872-7.
24. Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994; 121: 648-53.
25. Potter MN, Kennedy CTC, Mott MJ et al. Congenital systemic mastocytosis. Br J Dermatol 1990; 123 (Suppl. 37): 70-4.
26. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991; 96: 5-14S.
27. Fain O, Sitbon M, Sibony M et al. Efficacité de l'interféron alpha dans un cas de mastocytose systémique (letter). Ann Med Interne (Paris) 1995; 46: 205.
28. Delaporte E, Pierard E, Wolthers BG et al. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease (letter). Br J Dermatol 1995; 132: 479.
29. Czarnetzki BM, Algermissen B, Jeep S et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 1994; 30: 500-1.
30. Kolde G, Sunderkötter C, Luger TA. Treatment of urticaria pigmentosa using Interferon alpha. Br J Dermatol 1995; 133: 91-4.
31. Harrison BD, Ashford RA, Hatton CS. Systemic mastocytosis - a case treated with interferon alpha and radiotherapy. Clin Lab Haematol 1994; 16: 291-4.
32. Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD. Treatment of three patients with systemic mastocytosis with Interferon alpha-2b. Leuk Lymphoma 1996; 22: 501-8.
33. Sacchi S, Kantarjian H, O'Brien S et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401-7.
34. Pardini S, Bosincu L, Bonfigli S et al. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon (letter). Acta Haematol 1991; 85: 220.